Selected research
Market Analysis & Forecast
Global Pharmaceutical Drugs Market Analysis and Forecast 2026-2032
Market perspective
The global Pharmaceutical Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Pharmaceutical Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Pharmaceutical Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Pharmaceutical Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Pharmaceutical Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Pharmaceutical Drugs include Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck & Co. (MSD), AstraZeneca, AbbVie, AbbVie, Amgen and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Pharmaceutical Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Pharmaceutical Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmaceutical Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharmaceutical Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmaceutical Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmaceutical Drugs revenue, projected growth trends, production technology, application and end-user industry.
Pharmaceutical Drugs Segment by Company
Boehringer Ingelheim
Bristol-Myers Squibb
Gilead Sciences
Merck & Co. (MSD)
AstraZeneca
AbbVie
AbbVie
Amgen
Bayer
GlaxoSmithKline (GSK)
Pfizer
Eli Lilly
Roche
Novo Nordisk
Novartis
Johnson & Johnson
Sanofi
Teva
Takeda
Takeda
Pharmaceutical Drugs Segment by Type
Brand Drugs
Generic Drug
Pharmaceutical Drugs Segment by Application
Hospital
Clinic
Other
Pharmaceutical Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Pharmaceutical Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Pharmaceutical Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmaceutical Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Brand Drugs
- Generic Drug
Applications
- Hospital
- Clinic
- Other
Companies covered
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Gilead Sciences
- Merck & Co. (MSD)
- AstraZeneca
- AbbVie
- AbbVie
- Amgen
- Bayer
- GlaxoSmithKline (GSK)
- Pfizer
- Eli Lilly
- Roche
- Novo Nordisk
- Novartis
- Johnson & Johnson
- Sanofi
- Teva
- Takeda
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Pharmaceutical Drugs Market by Type
- 1.2.1 Global Pharmaceutical Drugs Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Brand Drugs
- 1.2.3 Generic Drug
- 1.3 Pharmaceutical Drugs Market by Application
- 1.3.1 Global Pharmaceutical Drugs Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pharmaceutical Drugs Market Dynamics
- 2.1 Pharmaceutical Drugs Industry Trends
- 2.2 Pharmaceutical Drugs Industry Drivers
- 2.3 Pharmaceutical Drugs Industry Opportunities and Challenges
- 2.4 Pharmaceutical Drugs Industry Restraints
3 Global Growth Perspective
- 3.1 Global Pharmaceutical Drugs Market Perspective (2021-2032)
- 3.2 Global Pharmaceutical Drugs Growth Trends by Region
- 3.2.1 Global Pharmaceutical Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Pharmaceutical Drugs Market Size by Region (2021-2026)
- 3.2.3 Global Pharmaceutical Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Pharmaceutical Drugs Revenue by Players
- 4.1.1 Global Pharmaceutical Drugs Revenue by Players (2021-2026)
- 4.1.2 Global Pharmaceutical Drugs Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Pharmaceutical Drugs Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Pharmaceutical Drugs Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Pharmaceutical Drugs Key Players Headquarters & Area Served
- 4.4 Global Pharmaceutical Drugs Players, Product Type & Application
- 4.5 Global Pharmaceutical Drugs Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Pharmaceutical Drugs Market CR5 and HHI
- 4.6.3 2025 Pharmaceutical Drugs Tier 1, Tier 2, and Tier 3
5 Pharmaceutical Drugs Market Size by Type
- 5.1 Global Pharmaceutical Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Pharmaceutical Drugs Revenue by Type (2021-2032)
- 5.3 Global Pharmaceutical Drugs Revenue Market Share by Type (2021-2032)
6 Pharmaceutical Drugs Market Size by Application
- 6.1 Global Pharmaceutical Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Pharmaceutical Drugs Revenue by Application (2021-2032)
- 6.3 Global Pharmaceutical Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Boehringer Ingelheim
- 7.1.1 Boehringer Ingelheim Company Information
- 7.1.2 Boehringer Ingelheim Business Overview
- 7.1.3 Boehringer Ingelheim Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.1.4 Boehringer Ingelheim Pharmaceutical Drugs Product Portfolio
- 7.1.5 Boehringer Ingelheim Recent Developments
- 7.2 Bristol-Myers Squibb
- 7.2.1 Bristol-Myers Squibb Company Information
- 7.2.2 Bristol-Myers Squibb Business Overview
- 7.2.3 Bristol-Myers Squibb Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.2.4 Bristol-Myers Squibb Pharmaceutical Drugs Product Portfolio
- 7.2.5 Bristol-Myers Squibb Recent Developments
- 7.3 Gilead Sciences
- 7.3.1 Gilead Sciences Company Information
- 7.3.2 Gilead Sciences Business Overview
- 7.3.3 Gilead Sciences Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.3.4 Gilead Sciences Pharmaceutical Drugs Product Portfolio
- 7.3.5 Gilead Sciences Recent Developments
- 7.4 Merck & Co. (MSD)
- 7.4.1 Merck & Co. (MSD) Company Information
- 7.4.2 Merck & Co. (MSD) Business Overview
- 7.4.3 Merck & Co. (MSD) Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.4.4 Merck & Co. (MSD) Pharmaceutical Drugs Product Portfolio
- 7.4.5 Merck & Co. (MSD) Recent Developments
- 7.5 AstraZeneca
- 7.5.1 AstraZeneca Company Information
- 7.5.2 AstraZeneca Business Overview
- 7.5.3 AstraZeneca Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.5.4 AstraZeneca Pharmaceutical Drugs Product Portfolio
- 7.5.5 AstraZeneca Recent Developments
- 7.6 AbbVie
- 7.6.1 AbbVie Company Information
- 7.6.2 AbbVie Business Overview
- 7.6.3 AbbVie Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.6.4 AbbVie Pharmaceutical Drugs Product Portfolio
- 7.6.5 AbbVie Recent Developments
- 7.7 AbbVie
- 7.7.1 AbbVie Company Information
- 7.7.2 AbbVie Business Overview
- 7.7.3 AbbVie Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.7.4 AbbVie Pharmaceutical Drugs Product Portfolio
- 7.7.5 AbbVie Recent Developments
- 7.8 Amgen
- 7.8.1 Amgen Company Information
- 7.8.2 Amgen Business Overview
- 7.8.3 Amgen Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.8.4 Amgen Pharmaceutical Drugs Product Portfolio
- 7.8.5 Amgen Recent Developments
- 7.9 Bayer
- 7.9.1 Bayer Company Information
- 7.9.2 Bayer Business Overview
- 7.9.3 Bayer Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.9.4 Bayer Pharmaceutical Drugs Product Portfolio
- 7.9.5 Bayer Recent Developments
- 7.10 GlaxoSmithKline (GSK)
- 7.10.1 GlaxoSmithKline (GSK) Company Information
- 7.10.2 GlaxoSmithKline (GSK) Business Overview
- 7.10.3 GlaxoSmithKline (GSK) Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.10.4 GlaxoSmithKline (GSK) Pharmaceutical Drugs Product Portfolio
- 7.10.5 GlaxoSmithKline (GSK) Recent Developments
- 7.11 Pfizer
- 7.11.1 Pfizer Company Information
- 7.11.2 Pfizer Business Overview
- 7.11.3 Pfizer Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.11.4 Pfizer Pharmaceutical Drugs Product Portfolio
- 7.11.5 Pfizer Recent Developments
- 7.12 Eli Lilly
- 7.12.1 Eli Lilly Company Information
- 7.12.2 Eli Lilly Business Overview
- 7.12.3 Eli Lilly Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.12.4 Eli Lilly Pharmaceutical Drugs Product Portfolio
- 7.12.5 Eli Lilly Recent Developments
- 7.13 Roche
- 7.13.1 Roche Company Information
- 7.13.2 Roche Business Overview
- 7.13.3 Roche Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.13.4 Roche Pharmaceutical Drugs Product Portfolio
- 7.13.5 Roche Recent Developments
- 7.14 Novo Nordisk
- 7.14.1 Novo Nordisk Company Information
- 7.14.2 Novo Nordisk Business Overview
- 7.14.3 Novo Nordisk Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.14.4 Novo Nordisk Pharmaceutical Drugs Product Portfolio
- 7.14.5 Novo Nordisk Recent Developments
- 7.15 Novartis
- 7.15.1 Novartis Company Information
- 7.15.2 Novartis Business Overview
- 7.15.3 Novartis Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.15.4 Novartis Pharmaceutical Drugs Product Portfolio
- 7.15.5 Novartis Recent Developments
- 7.16 Johnson & Johnson
- 7.16.1 Johnson & Johnson Company Information
- 7.16.2 Johnson & Johnson Business Overview
- 7.16.3 Johnson & Johnson Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.16.4 Johnson & Johnson Pharmaceutical Drugs Product Portfolio
- 7.16.5 Johnson & Johnson Recent Developments
- 7.17 Sanofi
- 7.17.1 Sanofi Company Information
- 7.17.2 Sanofi Business Overview
- 7.17.3 Sanofi Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.17.4 Sanofi Pharmaceutical Drugs Product Portfolio
- 7.17.5 Sanofi Recent Developments
- 7.18 Teva
- 7.18.1 Teva Company Information
- 7.18.2 Teva Business Overview
- 7.18.3 Teva Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.18.4 Teva Pharmaceutical Drugs Product Portfolio
- 7.18.5 Teva Recent Developments
- 7.19 Takeda
- 7.19.1 Takeda Company Information
- 7.19.2 Takeda Business Overview
- 7.19.3 Takeda Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.19.4 Takeda Pharmaceutical Drugs Product Portfolio
- 7.19.5 Takeda Recent Developments
- 7.20 Takeda
- 7.20.1 Takeda Company Information
- 7.20.2 Takeda Business Overview
- 7.20.3 Takeda Pharmaceutical Drugs Revenue and Gross Margin (2021-2026)
- 7.20.4 Takeda Pharmaceutical Drugs Product Portfolio
- 7.20.5 Takeda Recent Developments
8 North America
- 8.1 North America Pharmaceutical Drugs Revenue (2021-2032)
- 8.2 North America Pharmaceutical Drugs Revenue by Type (2021-2032)
- 8.2.1 North America Pharmaceutical Drugs Revenue by Type (2021-2026)
- 8.2.2 North America Pharmaceutical Drugs Revenue by Type (2027-2032)
- 8.3 North America Pharmaceutical Drugs Revenue Share by Type (2021-2032)
- 8.4 North America Pharmaceutical Drugs Revenue by Application (2021-2032)
- 8.4.1 North America Pharmaceutical Drugs Revenue by Application (2021-2026)
- 8.4.2 North America Pharmaceutical Drugs Revenue by Application (2027-2032)
- 8.5 North America Pharmaceutical Drugs Revenue Share by Application (2021-2032)
- 8.6 North America Pharmaceutical Drugs Revenue by Country
- 8.6.1 North America Pharmaceutical Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Pharmaceutical Drugs Revenue by Country (2021-2026)
- 8.6.3 North America Pharmaceutical Drugs Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Pharmaceutical Drugs Revenue (2021-2032)
- 9.2 Europe Pharmaceutical Drugs Revenue by Type (2021-2032)
- 9.2.1 Europe Pharmaceutical Drugs Revenue by Type (2021-2026)
- 9.2.2 Europe Pharmaceutical Drugs Revenue by Type (2027-2032)
- 9.3 Europe Pharmaceutical Drugs Revenue Share by Type (2021-2032)
- 9.4 Europe Pharmaceutical Drugs Revenue by Application (2021-2032)
- 9.4.1 Europe Pharmaceutical Drugs Revenue by Application (2021-2026)
- 9.4.2 Europe Pharmaceutical Drugs Revenue by Application (2027-2032)
- 9.5 Europe Pharmaceutical Drugs Revenue Share by Application (2021-2032)
- 9.6 Europe Pharmaceutical Drugs Revenue by Country
- 9.6.1 Europe Pharmaceutical Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Pharmaceutical Drugs Revenue by Country (2021-2026)
- 9.6.3 Europe Pharmaceutical Drugs Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Pharmaceutical Drugs Revenue (2021-2032)
- 10.2 China Pharmaceutical Drugs Revenue by Type (2021-2032)
- 10.2.1 China Pharmaceutical Drugs Revenue by Type (2021-2026)
- 10.2.2 China Pharmaceutical Drugs Revenue by Type (2027-2032)
- 10.3 China Pharmaceutical Drugs Revenue Share by Type (2021-2032)
- 10.4 China Pharmaceutical Drugs Revenue by Application (2021-2032)
- 10.4.1 China Pharmaceutical Drugs Revenue by Application (2021-2026)
- 10.4.2 China Pharmaceutical Drugs Revenue by Application (2027-2032)
- 10.5 China Pharmaceutical Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Pharmaceutical Drugs Revenue (2021-2032)
- 11.2 Asia Pharmaceutical Drugs Revenue by Type (2021-2032)
- 11.2.1 Asia Pharmaceutical Drugs Revenue by Type (2021-2026)
- 11.2.2 Asia Pharmaceutical Drugs Revenue by Type (2027-2032)
- 11.3 Asia Pharmaceutical Drugs Revenue Share by Type (2021-2032)
- 11.4 Asia Pharmaceutical Drugs Revenue by Application (2021-2032)
- 11.4.1 Asia Pharmaceutical Drugs Revenue by Application (2021-2026)
- 11.4.2 Asia Pharmaceutical Drugs Revenue by Application (2027-2032)
- 11.5 Asia Pharmaceutical Drugs Revenue Share by Application (2021-2032)
- 11.6 Asia Pharmaceutical Drugs Revenue by Country
- 11.6.1 Asia Pharmaceutical Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Pharmaceutical Drugs Revenue by Country (2021-2026)
- 11.6.3 Asia Pharmaceutical Drugs Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Pharmaceutical Drugs Revenue (2021-2032)
- 12.2 SAMEA Pharmaceutical Drugs Revenue by Type (2021-2032)
- 12.2.1 SAMEA Pharmaceutical Drugs Revenue by Type (2021-2026)
- 12.2.2 SAMEA Pharmaceutical Drugs Revenue by Type (2027-2032)
- 12.3 SAMEA Pharmaceutical Drugs Revenue Share by Type (2021-2032)
- 12.4 SAMEA Pharmaceutical Drugs Revenue by Application (2021-2032)
- 12.4.1 SAMEA Pharmaceutical Drugs Revenue by Application (2021-2026)
- 12.4.2 SAMEA Pharmaceutical Drugs Revenue by Application (2027-2032)
- 12.5 SAMEA Pharmaceutical Drugs Revenue Share by Application (2021-2032)
- 12.6 SAMEA Pharmaceutical Drugs Revenue by Country
- 12.6.1 SAMEA Pharmaceutical Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Pharmaceutical Drugs Revenue by Country (2021-2026)
- 12.6.3 SAMEA Pharmaceutical Drugs Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst